Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Darlene Bartilucci

Family Medicine Jacksonville, FL Medical Doctor

NPI 1639156276 CMS profile 118945

3101 University Blvd S Ste 102, Jacksonville, FL 32216

Open in the dashboard

General payments

$12,885

540 records reported · program years 2019–2025

Research payments

$1,858

Paid to them · 11 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,059,426 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Darlene Bartilucci of Jacksonville, FL is reported in the CMS Open Payments database as having received $12,885 across 540 general payments and $1,858 in research payments paid to them. Separately, studies naming them as principal investigator received $3,059,426 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,613 68
2024 General $1,318 63
2024 Research $1,858 11
2023 General $1,695 81
2022 General $1,039 65
2021 General $722 44
2020 General $1,706 103
2019 General $3,791 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darlene Bartilucci
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Darlene Bartilucci were reported at $2,613. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Darlene Bartilucci Family Medicine median Middle half National median
2019 $3,791 $150 $41–$543 $163
2020 $1,706 $120 $32–$415 $114
2021 $722 $137 $35–$551 $132
2022 $1,039 $137 $37–$512 $149
2023 $1,695 $149 $42–$545 $160
2024 $1,318 $156 $44–$560 $164
2025 $2,613 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk AS $2,001 4 payments
  2. AbbVie, Inc. $1,622 29 payments
  3. GlaxoSmithKline, LLC. $1,124 55 payments
  4. AstraZeneca Pharmaceuticals LP $977 60 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $868 42 payments
  6. Pfizer Inc. $868 57 payments
  7. Novo Nordisk Inc $639 39 payments
  8. Lilly USA, LLC $563 41 payments
  9. Merck Sharp & Dohme Corporation $527 27 payments
  10. Abbott Laboratories $481 18 payments
  11. Other $3,214 168 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,295 533 payments
  2. Travel and Lodging $2,580 5 payments
  3. Education $9 2 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $538 29 payments
  2. ELIQUIS $408 24 payments
  3. FARXIGA $406 23 payments
  4. RYBELSUS $376 20 payments
  5. AIRSUPRA $374 20 payments
  6. Ozempic $359 21 payments
  7. SHINGRIX $345 22 payments
  8. MOUNJARO $272 16 payments
  9. JARDIANCE $267 16 payments
  10. FreeStyle Libre 2 $250 7 payments
  11. Other $9,696 581 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,858 11 payments

Prescribing to Medicare patients

Part D · data year 2024 · 119 drugs

Part D claims

5,786

Median for Family Practice: 1,826

Drug cost

$331,498

Median for Family Practice: $120,094

Branded share of claims

15.4%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 52 $64,842
Jardiance Empagliflozin Brand 31 $29,486
Mounjaro Tirzepatide Brand 27 $29,391
Prezcobix Darunavir/Cobicistat Brand 12 $29,123
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 35 $25,131
Trulicity Dulaglutide Brand 19 $24,665
Eliquis Apixaban Brand 28 $22,999
Myrbetriq Mirabegron Brand 13 $12,305
Trintellix Vortioxetine Hydrobromide Brand 14 $8,324
Gabapentin Generic 181 $3,576

The 10 drugs with the highest cost, of 119 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$113,858

Of which drugs: $32,223

Medicare patients

245

Average age 75

Services billed

2,564

177 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 34%
Diabetes 30%
Chronic kidney disease 26%
Depression 26%
COPD 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 41 41 $11,837
Vaccine for influenza for injection into muscle 90662 Office 107 112 $9,003
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 14 70 $63

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $176
$176 — —
MOUNJARO
  • Lilly USA, LLC $109
$109 27 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $69
  • Lilly USA, LLC $36
$105 31 —
GARDASIL 9
  • Merck Sharp & Dohme Corporation $50
$50 — —
GARDASIL
  • Merck Sharp & Dohme Corporation $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

551 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record